120 related articles for article (PubMed ID: 6256153)
1. Orally active mineralocorticoid agonists and antagonists: delta 1-derivatives of aldosterone and 18-deoxyaldosterone.
Adam WR; Funder JW; Ulick S
Endocrinology; 1981 Feb; 108(2):517-21. PubMed ID: 6256153
[TBL] [Abstract][Full Text] [Related]
2. The mineralocorticoid antagonist activity of an 11 beta,18-oxidopregnane.
Ulick S; Marver D; Adam WR; Funder JW
Endocrinology; 1979 May; 104(5):1352-6. PubMed ID: 436780
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid and renal receptor binding activity of 21-deoxyaldosterone.
Koshida H; Miyamori I; Soma R; Matsubara T; Ikeda M; Takeda R; Nakamura S; Kiuchi F; Tsuda Y
Endocrinology; 1990 Mar; 126(3):1410-5. PubMed ID: 2155101
[TBL] [Abstract][Full Text] [Related]
4. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
[TBL] [Abstract][Full Text] [Related]
5. Occupancy of aldosterone binding sites in rat kidney cytosol.
Warnock DG; Edelman IS
Mol Cell Endocrinol; 1978 Nov; 12(2):221-33. PubMed ID: 215476
[TBL] [Abstract][Full Text] [Related]
6. A new subset of mineralocorticoid hypertension with excess of 21-deoxyaldosterone and Kelly's-M1 steroid: clinical and morphological findings.
Abdelhamid S; Lewicka S; Vecsei P; Haack D; Pahl S; Remberger K; Müller-Lobeck H; Bönhof JA; Nensel U; Röckel A
J Clin Endocrinol Metab; 1995 Mar; 80(3):737-44. PubMed ID: 7883826
[TBL] [Abstract][Full Text] [Related]
7. Cyproheptadine and mineralocorticoid effector mechanisms.
Armanini D; Goland GJ; Adam WR; Funder JW
J Clin Endocrinol Metab; 1983 Feb; 56(2):397-400. PubMed ID: 6296186
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid activity of 21-deoxyaldosterone derivatives: structure-function studies.
Wynne KN; Rae ID; O'Keefe DF; Adam WR; Pearce P; Stockigt JR; Funder JW
J Steroid Biochem; 1981 Oct; 14(10):1041-4. PubMed ID: 6272022
[No Abstract] [Full Text] [Related]
9. Receptor binding and biological activity of 18-hydroxycortisol.
Gomez-Sanchez EP; Gomez-Sanchez CE; Smith JS; Ferris MW; Foecking M
Endocrinology; 1984 Aug; 115(2):462-6. PubMed ID: 6086271
[TBL] [Abstract][Full Text] [Related]
10. RU-26988--a new tool for the study of the mineralocorticoid receptor.
Gomez-Sanchez CE; Gomez-Sanchez EP
Endocrinology; 1983 Sep; 113(3):1004-9. PubMed ID: 6307658
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid activity of 19-hydroxyaldosterone, 19-nor-aldosterone, and 3 beta-hydroxy-delta 5-aldosterone: relative potencies measured in two bioassay systems.
Morris DJ; Brem AS; Saccoccio NA; Pacholski M; Harnik M
Endocrinology; 1986 Jun; 118(6):2505-9. PubMed ID: 3084221
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone blockade in cardiovascular disease.
Struthers AD
Heart; 2004 Oct; 90(10):1229-34. PubMed ID: 15367532
[No Abstract] [Full Text] [Related]
13. Aldosterone antagonists. 1. Synthesis and biological activities of 11 beta,18-epoxypregnane derivatives.
Kamata S; Haga N; Mitsugi T; Kondo E; Nagata W; Nakamura M; Miyata K; Odaguchi K; Shimizu T; Kawabata T
J Med Chem; 1985 Apr; 28(4):428-33. PubMed ID: 2984418
[TBL] [Abstract][Full Text] [Related]
14. Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors.
Ulmann A; Menard J; Corvol P
Endocrinology; 1975 Jul; 97(1):46-51. PubMed ID: 166832
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
Kamata S; Matsui T; Haga N; Nakamura M; Odaguchi K; Itoh T; Shimizu T; Suzuki T; Ishibashi M; Yamada F
J Med Chem; 1987 Sep; 30(9):1647-58. PubMed ID: 3040999
[TBL] [Abstract][Full Text] [Related]
16. 16Beta-hydroxydehydroepiandrosterone: the dichotomy between renal receptor binding and urinary electrolyte activity.
Funder JW; Robinson JA; Feldman D; Wynne KN; Adam WR
Endocrinology; 1976 Aug; 99(2):619-28. PubMed ID: 182463
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention.
Feldman D; Couropmitree C
J Clin Invest; 1976 Jan; 57(1):1-7. PubMed ID: 173739
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia.
Kuhnle U; Land M; Ulick S
J Clin Endocrinol Metab; 1986 May; 62(5):934-40. PubMed ID: 3007560
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of a new antialdosterone compound, prorenone.
Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Corvol P
Endocrinology; 1979 Apr; 104(4):1194-200. PubMed ID: 436757
[TBL] [Abstract][Full Text] [Related]
20. Relationships of the molecular structure of aldosterone derivatives with their binding affinity for mineralocorticoid receptor.
Yamakawa M; Ezumi K; Shiro M; Nakai H; Kamata S; Matsui T; Haga N
Mol Pharmacol; 1986 Dec; 30(6):585-9. PubMed ID: 3023811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
